MyFinsight
Home
Blog
About
Contact
Cash and cash
equivalents
$879,891K
Accounts receivable, net
$205,226K
Prepaid expenses and
other current assets
$62,914K
Marketable securities
$60,295K
Inventories
$32,980K
Total current assets
$1,241,306K
Equity method
investments
$61,529K
Intangible assets, net
$27,359K
Other assets
$18,620K
Operating lease
right-of-use assets
$17,226K
Property and equipment,
net
$4,941K
Accumulated deficit
-$3,985,237K
Treasury stock, at cost
7,597,172 shares as of...
$405,776K
Accumulated other
comprehensive income (loss)
-$8K
Total assets
$1,370,981K
Total bridgebio
stockholders deficit
-$2,278,363K
Additional paid-in capital
$2,112,454K
Common stock, 0.001 par
value 500,000,000...
$204K
Total liabilities,
redeemable convertible...
$1,370,981K
Total stockholders
deficit
-$2,267,924K
Redeemable convertible
noncontrolling interests
-$951K
Noncontrolling interests
$10,439K
Total liabilities
$3,639,856K
Deferred royalty
obligations, net
$871,185K
Total current
liabilities
$816,372K
2033 notes, 2031
notes, 2029 notes, and...
$741,402K
2033 notes, 2031
notes, 2029 notes, and...
$619,631K
2033 notes, 2031
notes, 2029 notes, and...
$565,045K
Operating lease
liabilities, net of current...
$14,216K
Deferred revenue, net of
current portion
$11,776K
Other long-term
liabilities
$229K
Unamortized debt discount
and issuance costs
$53,432K
Carrying value of
deferred royalty...
$905,336K
2027 notes, net
$547,483K
Other current
liabilities
$135,509K
Accrued research and
development liabilities
$54,430K
Accrued compensation
and benefits
$39,338K
Accounts payable
$29,058K
Deferred revenue,
current portion
$6,115K
Operating lease
liabilities, current portion
$4,439K
Fair value of
embedded derivative...
$19,281K
Accrued rebates and
other related costs
$59,784K
Accrued commercial
$36,963K
Deferred royalty
obligations, current portion
$21,488K
Accrued professional
services
$7,540K
Accrued interest
$5,188K
Other accrued
liabilities
$4,546K
Funding Agreement
$19,281K
Back
Back
Balance Sheet
BridgeBio Pharma, Inc. (BBIO)
BridgeBio Pharma, Inc. (BBIO)
source: myfinsight.com